Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Neurophth to Develop AAV Capsids with AAVnerGene for Ophthalmology

publication date: Jan 19, 2021

Neurophth Therapeutics of Wuhan partnered with Delaware's AAVnerGene to develop adeno-associated virus (AAV) capsids for next-gen ophthalmic gene therapies. Neurophth will make an initial cash payment to AAVnerGene to test about 100 AAV capsids. Within 6-12 months, Neurophth will complete preclinical studies on these capsids, and the two companies will select the most promising candidates for further development. AAVnerGene believes its platform selects the best AAV vector for each cell type based on transduction efficiency, immunity to the capsid and best manufacturing processes. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021